Eric Burak

593 total citations
22 papers, 354 citations indexed

About

Eric Burak is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, Eric Burak has authored 22 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pharmacology, 4 papers in Cellular and Molecular Neuroscience and 4 papers in Oncology. Recurrent topics in Eric Burak's work include Radiopharmaceutical Chemistry and Applications (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Anesthesia and Sedative Agents (3 papers). Eric Burak is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Anesthesia and Sedative Agents (3 papers). Eric Burak collaborates with scholars based in United States, United Kingdom and Canada. Eric Burak's co-authors include Lucy M. Anderson, Jerry M. Rice, James J. Vornov, Tharin Limsakun, Barbara S. Slusher, Neil Trushin, Steven G. Carmella, Ann B. Jones, Stephen S. Hecht and Janice L. Southers and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Eric Burak

20 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Burak United States 9 144 68 65 61 57 22 354
Zhongfu Zuo China 12 225 1.6× 32 0.5× 19 0.3× 52 0.9× 33 0.6× 44 477
Yukio Motoyama Japan 14 136 0.9× 63 0.9× 44 0.7× 37 0.6× 30 0.5× 39 641
Be‐Sheng Kuo United States 10 91 0.6× 33 0.5× 18 0.3× 12 0.2× 43 0.8× 29 318
Anita Chugh India 11 192 1.3× 98 1.4× 6 0.1× 61 1.0× 38 0.7× 21 514
尚三 山本 3 143 1.0× 38 0.6× 17 0.3× 56 0.9× 33 0.6× 3 555
Masaki Hashimoto Japan 12 147 1.0× 46 0.7× 33 0.5× 42 0.7× 49 0.9× 43 452
F. B. Ubatuba United Kingdom 10 145 1.0× 89 1.3× 14 0.2× 23 0.4× 16 0.3× 15 573
John P. Chism United States 8 94 0.7× 11 0.2× 12 0.2× 41 0.7× 183 3.2× 16 394
Xia Jiang China 12 130 0.9× 29 0.4× 7 0.1× 40 0.7× 25 0.4× 36 461

Countries citing papers authored by Eric Burak

Since Specialization
Citations

This map shows the geographic impact of Eric Burak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Burak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Burak more than expected).

Fields of papers citing papers by Eric Burak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Burak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Burak. The network helps show where Eric Burak may publish in the future.

Co-authorship network of co-authors of Eric Burak

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Burak. A scholar is included among the top collaborators of Eric Burak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Burak. Eric Burak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Metcalf, Julie, Natalie Grinshtein, John Forbes, et al.. (2023). Abstract A146: FPI-2068: A novel anti-EGFR/cMET, alpha-particle emitting, radioimmunoconjugate for cancer therapy. Molecular Cancer Therapeutics. 22(12_Supplement). A146–A146. 2 indexed citations
2.
3.
Forbes, John, et al.. (2021). Abstract LB130: Combination of IGF-1R targeted alpha therapy with Olaparib results in synergistic efficacy against colorectal and lung cancer xenografts. Cancer Research. 81(13_Supplement). LB130–LB130. 1 indexed citations
4.
Grinshtein, Natalie, Ryan Simms, Yaryna Storozhuk, et al.. (2019). IGF-1R Targeted Alpha Therapeutic FPI-1434 causes DNA Double-stranded Breaks and Induces Regression in Preclinical Models of Human Cancer. Journal of medical imaging and radiation sciences. 50(4). S86–S86. 1 indexed citations
5.
Juergens, Rosalyn A., Katherine Zukotynski, Daniel Juneau, et al.. (2019). A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.. Journal of Clinical Oncology. 37(15_suppl). TPS3152–TPS3152. 17 indexed citations
6.
Molnár, Ildikó, Eric Burak, John Forbes, Ryan Simms, & John F. Valliant. (2018). The next generation of radioimmunotherapy: Targeted alpha therapy (TAT). Annals of Oncology. 29. iii6–iii6.
7.
Gibiansky, Ekaterina, Michel Struys, Leonid Gibiansky, et al.. (2005). AQUAVANO (R) injection, a water-soluble prodrug of propofol, as a bolus injection. Anesthesiology. 103(4). 718–729. 18 indexed citations
8.
Visser, Saco J. de, Marieke L. de Kam, Dana Hilt, et al.. (2005). The central nervous system effects, pharmacokinetics and safety of the NAALADase‐inhibitor GPI 5693. British Journal of Clinical Pharmacology. 60(2). 128–136. 57 indexed citations
9.
Schywalsky, M., Harald Ihmsen, Alexander Tzabazis, et al.. (2003). Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats: Retracted. European Journal of Anaesthesiology. 20(3). 182–190. 22 indexed citations
10.
Majer, Pavel, Paul Jackson, Greg Delahanty, et al.. (2003). Synthesis and Biological Evaluation of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II:  Discovery of an Orally Active GCP II Inhibitor. Journal of Medicinal Chemistry. 46(10). 1989–1996. 91 indexed citations
11.
Schywalsky, M., Harald Ihmsen, Alexander Tzabazis, et al.. (2002). Pharmacokinetic/-dynamic modelling of the new propofol prodrug GPI-15715 in rats. European Journal of Anaesthesiology. 19(3). 217–218. 1 indexed citations
12.
Vanluchene, Ann L. G., Luc Van Bortel, James J. Vornov, Eric Burak, & Michel Struys. (2002). Pharmacodynamics of AQUAVANTM Injection, a Water-Soluble Prodrug of Propofol as a Bolus Injection : A Phase I Dose Escalation Comparison with DIPRIVAN©. Anesthesiology. 96(Sup 2). A455–A455. 1 indexed citations
13.
Anderson, Lucy M., Eric Burak, Daniel Logsdon, et al.. (1994). Suppression of in vivo clearance of N-nitrosodimethylamine in mice by cotreatment with ethanol.. Drug Metabolism and Disposition. 22(1). 43–49. 12 indexed citations
14.
15.
Anderson, Lucy M., Eric Burak, Thomas J. Moskal, et al.. (1992). Reduced blood clearance and increased urinary excretion of N-nitrosodimethylamine in patas monkeys exposed to ethanol or isopropyl alcohol.. PubMed. 52(6). 1463–8. 14 indexed citations
16.
Burak, Eric, et al.. (1991). Estimation of the fraction of the dose of N-nitrosodimethylamine metabolized to methylamine in rats. Cancer Letters. 58(1-2). 1–6. 5 indexed citations
17.
Harrington, George W., Harry M. Pylypiw, Lucy M. Anderson, et al.. (1990). Interspecies scaling of the pharmacokinetics of N-nitrosodimethylamine.. PubMed. 50(14). 4366–70. 13 indexed citations
18.
Burak, Eric, et al.. (1988). Pulmonary clearance of vasoactive drugs: N-oxidation of SK&F 86466 in the isolated perfused rat lung.. Journal of Pharmacology and Experimental Therapeutics. 245(2). 402–406. 1 indexed citations
19.
Burak, Eric, et al.. (1988). Pulmonary clearance of vasoactive drugs: N-oxidation of SK&F 86466 in the isolated perfused rat lung.. PubMed. 245(2). 402–6. 3 indexed citations
20.
Mico, Bruce A., et al.. (1987). In vivo inhibition of phenacetin oxidation by suicide substrate 1-aminobenzotriazole.. Drug Metabolism and Disposition. 15(2). 274–276. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhongfu Zuo Breakdown of academic impact, for papers by Yukio Motoyama Breakdown of academic impact, for papers by Be‐Sheng Kuo Breakdown of academic impact, for papers by Anita Chugh Breakdown of academic impact, for papers by 尚三 山本 Breakdown of academic impact, for papers by Masaki Hashimoto Breakdown of academic impact, for papers by F. B. Ubatuba Breakdown of academic impact, for papers by John P. Chism Breakdown of academic impact, for papers by Xia Jiang
Rankless by CCL
2026